Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.5.0.2
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Income Statement [Abstract]      
Revenues $ 60,740 $ 41,953 $ 12,202
Other income 7,592 15,898 17,170
Total revenues 68,332 57,851 29,372
Cost of revenues 69,051 79,215 36,771
Gross loss 719 21,364 7,399
Operating expenses:      
Research and development 901,030 1,088,966 1,059,285
Less - research and development grants (180,033) (129,220) (225,024)
Research and development, net 720,997 959,746 834,261
Sales and marketing 245,756 136,770 110,577
General and administrative 807,277 809,927 347,843
Total operating expenses 1,774,030 1,906,443 1,292,681
Operating loss 1,774,749 1,927,807 1,300,080
Financial expenses (income), net (1,094) 236,561 291,109
Net loss 1,773,655 2,164,368 1,591,189
Deemed dividend 1,842,061
Net loss attributable to holders of Ordinary shares $ 1,773,655 $ 4,006,429 $ 1,591,189
Net loss attributable to holders of Ordinary shares per share:      
Basic and diluted net loss attributable to holders of Ordinary shares per share $ 0.14 $ 1.24 $ 0.71
Weighted average number of ordinary shares used in computing basic and diluted net loss per share 12,745,710 3,222,644 2,226,900